Tobi
TOBI is an inhaled aminoglycoside antibacterial. It is formulated for inhalation using a nebulizer, allowing the medication to be delivered directly to the lungs to treat chronic Pseudomonas aeruginosa infections in cystic fibrosis patients while minimizing systemic side effects.
Dosage by Body Weight
The standard dose for adults and pediatric patients 6 years of age and older is one single-use ampule (300 mg) administered twice daily (12 hours apart) for a 28-day active cycle, followed by 28 days off the drug. It is not dosed by body weight.
- Body Weight
- Below 5 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and efficacy of TOBI have not been established in pediatric patients under 6 years of age.
- Body Weight
- 5-7 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and efficacy of TOBI have not been established in pediatric patients under 6 years of age.
- Body Weight
- 8-10 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and efficacy of TOBI have not been established in pediatric patients under 6 years of age.
- Body Weight
- 11-15 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and efficacy of TOBI have not been established in pediatric patients under 6 years of age.
- Body Weight
- 16-20 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and efficacy of TOBI have not been established in pediatric patients under 6 years of age.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not established | Not recommended | Safety and efficacy of TOBI have not been established in pediatric patients under 6 years of age. |
| 5-7 kg | Not established | Not recommended | Safety and efficacy of TOBI have not been established in pediatric patients under 6 years of age. |
| 8-10 kg | Not established | Not recommended | Safety and efficacy of TOBI have not been established in pediatric patients under 6 years of age. |
| 11-15 kg | Not established | Not recommended | Safety and efficacy of TOBI have not been established in pediatric patients under 6 years of age. |
| 16-20 kg | Not established | Not recommended | Safety and efficacy of TOBI have not been established in pediatric patients under 6 years of age. |
Formulation
Purpose
Management of cystic fibrosis patients with Pseudomonas aeruginosa infections to improve lung function and reduce bacterial count.
Generic Name
TobramycinScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.